<DOC>
	<DOCNO>NCT01947933</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3074828 . The study investigate body process study drug drug affect body . The study last 3 month participant .</brief_summary>
	<brief_title>A Safety Study LY3074828</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion Criteria ( Psoriasis participant ) : Chronic plaque psoriasis base investigator confirm diagnosis chronic psoriasis vulgaris least 6 month prior baseline Plaque psoriasis involve &gt; 2 % body surface area ( BSA ) affect skin face scalp screen baseline Are willing able washout topicals least 14 day baseline 2 target lesion Inclusion Criteria ( Healthy participant ) : Are overtly healthy male female , determine medical history physical examination Are woman childbearing potential Are age 18 65 year , inclusive , time screen Have body mass index 18.5 32.0 kilogram per square meter ( kg/m2 ) , inclusive , minimum body weight 55 kg Have clinical laboratory test result within normal reference range central laboratory , result acceptable deviation judge clinically significant investigator Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ERB govern site Exclusion Criteria ( Psoriasis healthy participant ) : Have receive treatment biologic therapy psoriasis ( monoclonal antibody , include market investigational biologic therapy ) . Prior current use biologics indication psoriasis may allow sponsor approval Within 28 day prior baseline : receive systemic nonbiologic psoriasis therapy Within 14 day prior baseline : receive topical psoriasis treatment Have presence significant uncontrolled cerebrocardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic , neurologic neuropsychiatric disorder abnormal laboratory value screen , opinion investigator , pose unacceptable risk subject participate study interfere interpretation data Have clinically significant symptomatic herpes zoster within 3 month screen Show evidence active latent tuberculosis ( TB ) Have receive live vaccine ( ) ( include attenuate live vaccine ) within 1 month screen intend study Have significant allergy humanize monoclonal antibody component LY3074828 product formulation history significant atopy Have lymphoma , leukemia , malignancy within past 5 year , except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease 3 year cervical carcinoma situ , evidence recurrence within 5 year prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>